Natera Inc (NTRA)

May 8, 2025, 8:58 PM EDT - 5 days ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 5 days ago

Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 10:30 AM EDT - 6 days ago

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 7, 2025, 7:00 AM EDT - 7 days ago

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 5, 2025, 7:00 AM EDT - 9 days ago

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 1, 2025, 7:00 AM EDT - 13 days ago

Natera to Report its First Quarter Results on May 8, 2025

Apr 29, 2025, 4:05 PM EDT - 14 days ago

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Apr 29, 2025, 11:45 AM EDT - 14 days ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK PEN TMO UNH

Apr 24, 2025, 7:00 AM EDT - 20 days ago

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Apr 22, 2025, 4:05 PM EDT - 21 days ago

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Mar 25, 2025, 7:00 AM EDT - 7 weeks ago

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Mar 17, 2025, 11:52 AM EDT - 2 months ago

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

Mar 10, 2025, 8:00 AM EDT - 2 months ago

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Mar 4, 2025, 7:00 AM EST - 2 months ago

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Feb 28, 2025, 12:23 AM EST - 2 months ago

Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 2 months ago

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 6:00 AM EST - 2 months ago

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Feb 18, 2025, 9:00 AM EST - 3 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

Feb 10, 2025, 7:00 AM EST - 3 months ago

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Feb 3, 2025, 7:00 AM EST - 3 months ago

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

Jan 25, 2025, 10:05 AM EST - 3 months ago

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Jan 21, 2025, 6:05 PM EST - 4 months ago

Natera to Present New Data at the 2025 ASCO GI Symposium

Jan 17, 2025, 9:00 AM EST - 4 months ago

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Jan 15, 2025, 7:00 AM EST - 4 months ago

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

Jan 12, 2025, 7:20 PM EST - 4 months ago

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Jan 7, 2025, 9:00 AM EST - 4 months ago

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 2:00 PM EST - 4 months ago

Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +

LYG PRIM

Dec 31, 2024, 5:50 AM EST - 4 months ago

Natera: Poised For A Great Future But I'd Wait For A Pullback

Dec 20, 2024, 2:27 PM EST - 5 months ago

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Dec 17, 2024, 8:00 AM EST - 5 months ago

Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Dec 12, 2024, 8:00 AM EST - 5 months ago

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Dec 9, 2024, 8:00 AM EST - 5 months ago

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Dec 2, 2024, 8:00 AM EST - 5 months ago

Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology

Nov 27, 2024, 9:00 AM EST - 6 months ago

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients

Nov 25, 2024, 7:57 PM EST - 6 months ago

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium

Nov 25, 2024, 5:09 PM EST - 6 months ago

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

GH

Nov 25, 2024, 3:51 PM EST - 6 months ago

Natera Issues Statement on Guardant Health Litigation

Nov 25, 2024, 9:00 AM EST - 6 months ago

Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year

Nov 21, 2024, 5:31 PM EST - 6 months ago

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Nov 12, 2024, 11:51 PM EST - 6 months ago

Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 6 months ago

Natera Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 7:00 AM EST - 6 months ago

Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Nov 8, 2024, 9:00 AM EST - 6 months ago

Natera to Participate in Upcoming Investor Conferences

Nov 1, 2024, 9:00 AM EDT - 6 months ago

Natera to Report its Third Quarter 2024 Results on November 12, 2024

Oct 31, 2024, 6:00 AM EDT - 6 months ago

Cigna Turns $739 Million Profit Despite $1 Billion Loss On VillageMD

CI

Oct 22, 2024, 9:00 AM EDT - 7 months ago

Natera to Present New Renasight Data at ASN Kidney Week 2024

Sep 23, 2024, 4:06 PM EDT - 8 months ago

Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase

Sep 16, 2024, 5:17 AM EDT - 8 months ago

Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO

Sep 14, 2024, 2:16 PM EDT - 8 months ago

First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival

Sep 8, 2024, 8:22 PM EDT - 8 months ago

Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival